US equities |
META $620.18 ▼-1.65% TSLA $407.06 ▲+3.94% MU $928.33 ▲+2.73% NVDA $217.96 ▲+0.91% SPCX $148.58 ▲+1.14% AMD $559.77 ▲+5.36% AAPL $347.16 ▲+0.95% SNDK $1,304.44 ▲+3.89%
FinancialContent

Oncotelic Therapeutcs Inc (OP:OTLC)

0.0189 +0.0026 (+15.95%)
Delayed Quote Updated: 3:55 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oncotelic Therapeutcs Inc

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oncotelic Announces Formation of Animal Health Division
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting
From Oncotelic Therapeutics, Inc.
Via GlobeNewswire
News headline image
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal ↗
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and... 
Via Talk Markets
News headline image
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022
Oncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022 
Via News Direct
News headline image
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY
ONCOTELIC ANNOUNCES POSITIVE TOPLINE DATA FOR OT-101 C001 COVID STUDY 
Via News Direct
Topics Artificial Intelligence Regulatory Compliance
< Previous 1 2 3 4 5 6 7 Next >